Transporter (TAP)- and proteasome-independent presentation of a melanoma-associated tyrosinase epitope

International Journal of Cancer

Volumn 88, Issue 3, 2000, Pages 432-438

  Wölfel, Catherine ^a   Drexler, Ingo ^b   Van Pel, Aline ^c   Thres, Tanja ^a   Leister, Nicole ^a   Herr, Wolfgang ^a   Sutter, Gerd ^d   Huber, Christoph ^a   Wölfel, Thomas ^a,e  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

^e UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; EPITOPE; HLA A2 ANTIGEN; LACTACYSTIN; LYMPHOKINE; MONOPHENOL MONOOXYGENASE; PEPTIDE [1-9]; PEPTIDE [369-377]; PEPTIDE DERIVATIVE; PROTEASOME; SIGNAL PEPTIDE; TAP TRANSPORTER; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; MELANOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN TARGETING; PROTEIN TRANSPORT; TARGET CELL; VACCINIA VIRUS;

ANTIGEN PRESENTATION; ATP-BINDING CASSETTE TRANSPORTERS; CYSTEINE ENDOPEPTIDASES; EPITOPES; HLA-A2 ANTIGEN; HUMAN; MELANOMA; MONOPHENOL MONOOXYGENASE; MULTIENZYME COMPLEXES; PROTEIN SORTING SIGNALS; SUPPORT, NON-U.S. GOV'T; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0033819693     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(20001101)88:3<432::AID-IJC16>3.0.CO;2-9     Document Type: Article

References (52)

1. Identification of a TAP-dependent leader peptide recognized by alloreactive T cells specific for a class Ib antigen
2. Endogenously synthesized peptide with an endoplasmic reticulum signal sequence sensitizes antigen processing mutant cells to class I-restricted cell-mediated lysis
3. b
4. The effect of the proteasome inhibitor lactacystin on the presentation of transporter associated with antigen processing (TAP)-dependent and TAP-independent peptide epitopes by class I molecules
5. Proteasome and class I antigen processing and presentation
6. Tumor antigens recognized by T cells
7. The human major histocompatibility complex class 1b molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9
8. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lympocytes on HLA-A2 melanomas
9. A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes
10. A cytoplasmic sequence in human tyrosinase defines a second class of di-leucine-based sorting signals for late endosomal and lysosomal delivery
11. MART-1 is expressed less frequently on circulating melanoma cells in patients who develop distant compared with locoregional metastases
12. Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: Induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo
13. Processing of major histocompatibility class I-restricted antigens in the endoplasmic reticulum
14. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin
15. The proteasome inhibitor lactacystin prevents the generation of an endoplasmic reticulum leader-derived T cell epitope
16. Aberrant retention of tyrosinase in the endoplasmic reticulum mediates accelerated degradation of the enzyme and contributes to the dedifferentiated phenotype of amelanotic melanoma cells
17. Direct identification of an endogenous peptide recognized by multiple HLA-A2.1-specific cytotoxic T cells
18. HLA-A2.1-associated peptides from a mutant cell line: A second pathway of antigen presentation
19. + T lymphocytes producing tumor necrosis factor alpha spots in response to peptide antigens
20. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo
21. Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes
22. Interferon-alpha and interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trials
23. Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: Implications for tumor vaccine development
24. Brefeldin A: Insights into the control of membrane traffic and organelle structure
25. Tyrosinase epitope recognized by an HLA-DR-restricted T-cell line from a Vogt-Koyanagi-Harada disease patient
26. HLA-E surface expression depends on binding of TAP-dependent peptides derived from certain HLA class I signal sequences
27. Transporter (TAP)-independent processing of a multiple membrane-spanning protein, the Epstein-Barr virus latent membrane protein 2
28. Tumor escape from immune recognition: Lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen
29. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
30. Proteasome subunits encoded by the major histocompatibitity complex are not essential for antigen presentation
31. A tyrosinase peptide presented by HLA-B35 is recognized on a human melanoma by autologous cytotoxic T lymphocytes
32. The class I antigen-processing pathway for the membrane protein tyrosinase involves translation in the endoplasmic reticulum and processing in the cytosol
33. Counting antigen-specific CD8 T cells: A reevaluation of bystander activation during viral infection
34. Identification of human cancers deficient in antigen-processing
35. The antigen-processing mutant T2 suggests a role for MHC-linked genes in class II antigen presentation
36. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201 restricted Melan-A/MART-1 antigenic peptide in melanoma
37. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine
38. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids
39. TAP off - Tumors on
40. Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100
41. An HLA-A2-restricted tyrosinase antigen on melanoma cells resulted from posttranslational modification and suggests a novel pathway for processing of membrane proteins
42. Trimming of antigenic peptides in an early secretory compartment
43. + T cells specific for EBV in healthy virus carriers
44. + T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes
45. + T cells binds very tightly to the restricting class I major histocompatibility complex protein on intact cells but not to the purified class I protein
46. CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells
47. Protein translocation across the endoplasmic reticalum
48. + T cell responses
49. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides
50. Lysis of human pancreatic adenocarcinoma cells by autologous HLA-class I-restricted cytolytic T-lymphocyte (CTL) clones
51. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes
52. TAP-independent delivery of antigenic peptides to the endoplasmic reticulum: Therapeutic potential and insights into TAP-dependent antigen processing